LNTH - Perspective Therapeutics: An Elevated Theranostics Play Flying Under Your Radar
2024-05-27 11:42:55 ET
Summary
- Perspective Therapeutics is working on a novel modality of peptide receptor radionuclide therapy.
- They have encouraging very early data and a recently shored up cash runway now lasting several years.
- A high market valuation makes this equity a very risky move at this time, despite potential catalysts.
Topline Summary
Perspective Therapeutics (CATX) is an oncology-focused biotech looking to make a contribution to the slow-growing but high-interest field of theranostics, a form of treatment that combines diagnostic techniques with therapeutic modalities in an attempt to precisely target tumor biology and improve standards of care. They have multiple agents in clinical trials across various solid tumors. Today, I want to provide a look at this company and how the investment thesis is shaping up at the current market cap of $1 billion....
Perspective Therapeutics: An Elevated Theranostics Play Flying Under Your Radar